Treatment
Cell clinical trials
We’re tracking 5,684 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT06524427Recruiting
Robot vs. video-assisted lung cancer surgery study
This trial compares robot-assisted surgery to video-assisted surgery for removing lung cancer. It aims to see which approach works better for patients with early-stage non-small cell lung cancer.
Chongqing, Chongqing MunicipalityAges 18–80 - NCT06525220RecruitingPhase 3
New drug combo vs. standard for head and neck cancer
This trial tests a new combination of two immunotherapy drugs (petosemtamab plus pembrolizumab) compared to pembrolizumab alone for people with head and neck cancer that has spread or come back and cannot be cured locally. It may be an option if your cancer has a certain protein (PD-L1) and you haven't had prior cancer treatment for this stage.
Mobile, AlabamaAges 18 years+ - NCT06526065Recruiting
Understanding lymphoma biology to improve treatment
This study looks at the biology of certain lymphomas to better understand why some people respond well to treatment and others don't. It involves giving a small additional blood or tissue sample to help researchers find genetic clues that could improve future care.
Göttingen, Lower SaxonyAges 18–85 - NCT06526117RecruitingPhase 4
Stroke Prevention in Nigeria 2 Trial
This trial tests whether giving hydroxyurea (a medicine that helps prevent strokes) to children with sickle cell disease who have high-risk blood flow in their brains can stop strokes from happening. It's for kids in Nigeria who are at the peak age for stroke risk (5–12 years old).
KanoAges 5–12 - NCT06528847RecruitingPhase 2
Adjuvant Benmelstobart for stage IB, grade 3 lung adenocarcinoma
This trial tests whether giving the immunotherapy drug Benmelstobart after surgery can help prevent return of a specific type of lung cancer. It is for people with stage IB, grade 3 (poorly differentiated) lung adenocarcinoma that has been completely removed.
Shanghai, Shanghai MunicipalityAges 18–74 - NCT06529874Recruiting
Pain, balance, and strength in children with sickle cell
This study looks at how children (ages 9-14) with sickle cell anemia or who are healthy handle pressure, balance, and strength. It aims to understand pain and movement better to help improve care.
GizaAges 9–14 - NCT06530511RecruitingPhase 2
PRO trial for elderly, frail patients with a type of lymphoma
This trial tests a combination of three drugs (Polatuzumab, Rituximab, and Orelabrutinib) for elderly patients who are frail or over 80 with a specific type of untreated diffuse large B-cell lymphoma (non-GCB DLBCL). The goal is to see if this drug combo is safe and effective for those who may not tolerate standard chemotherapy.
Nantong, JiangsuAges 60 years+ - NCT06530550RecruitingPhase 2
PI3K inhibitor for relapsed T/NK-cell lymphoma
This trial tests a targeted therapy called a PI3K inhibitor for people whose T-cell or NK-cell lymphoma has returned or not improved after other treatments. It aims to see if the drug can shrink or control the lymphoma.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06534489Recruiting
Surgery for lung cancer after chemo or targeted therapy
This trial tests whether combining chemo or targeted therapy before surgery can help people with non-small cell lung cancer that may require removing a whole lung. We want to see if this approach makes the surgery safer and more effective.
ShanghaiAges 18–75 - NCT06536127Recruiting
Immune cells in non-spreading rectal cancer treatment
This study is looking at immune cells (NK cells and ImmunoScore) in the blood of people with rectal cancer that hasn't spread. It may help doctors learn more about how the immune system responds to standard chemoradiation treatment.
AvignonAges 18 years+ - NCT06536413RecruitingPhase 1/Phase 2
ATRA and Carfilzomib for multiple myeloma
This trial tests if combining the drug ATRA with carfilzomib can help people with multiple myeloma whose cancer has come back or stopped responding to at least three prior treatments, including carfilzomib. The goal is to see if this new combination works better than carfilzomib alone.
Houston, TexasAges 18 years+ - NCT06536452Recruiting
How blood cell production differs in CLL, MBL, and healthy people
This trial studies how the body makes blood cells in people with chronic lymphocytic leukemia (CLL), a related condition called monoclonal B-cell lymphocytosis (MBL), and in healthy volunteers matched by age. The goal is to understand differences that may help improve treatment or monitoring.
Rochester, MinnesotaAges 40 years+ - NCT06536439Recruiting
Digital tool to plan kidney clamping during robotic surgery
This trial tests a new digital tool that helps surgeons plan the best way to clamp the blood supply to your kidney during robotic surgery. The tool aims to reduce damage to healthy kidney tissue while still blocking the tumor's blood flow.
AalstAges 18 years+ - NCT06536868RecruitingPhase 2
Tislelizumab with chemo and radiation for extensive-stage small cell lung cancer
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and chest radiation for people with extensive-stage small cell lung cancer (SCLC) that has spread. The goal is to see if this combination helps shrink or control the cancer longer.
Jincheng, ShanxiAges 18–80 - NCT06538012RecruitingPhase 1/Phase 2
Tumor immune cells plus pembrolizumab for advanced lung cancer
This trial tests a new approach: taking immune cells from your own tumor (TILs), growing them in the lab, then giving them back to you along with the immunotherapy drug pembrolizumab. It is for people with advanced lung cancer who have run out of standard options.
Beijing, Beijing MunicipalityAges 16–90 - NCT06538038Recruiting
Osimertinib plus chemo vs. osimertinib alone for EGFR-mutated NSCLC
This study compares two standard treatments for advanced lung cancer with an EGFR mutation: osimertinib alone versus osimertinib plus chemotherapy. It aims to see which approach works better and is not a trial of a new drug, so you can receive usual care while contributing data.
Birmingham, AlabamaAges 18 years+ - NCT06539169Recruiting
Following people with rare diseases over time
This study follows people with rare diseases over time to learn more about how these conditions progress and how they are treated. Joining may help researchers understand your disease better and find better ways to care for others.
Los Altos, CaliforniaAges Any age - NCT06541067RecruitingPhase 2
Posaconazole to prevent fungal infections after stem cell transplant
This trial tests whether the antifungal drug posaconazole can prevent serious fungal infections in people who are at high risk after a stem cell transplant. If you qualify, you would take posaconazole during your recovery.
Nantes, FranceAges 18 years+ - NCT06543381RecruitingPhase 1
Olutasidenib for IDH1-mutated blood cancers after transplant
This trial tests a drug called olutasidenib for people with certain blood cancers (AML, MDS, or CMML) that have a specific IDH1 gene change. The goal is to see if it can help prevent relapse after a donor stem cell transplant.
Duarte, CaliforniaAges 18 years+ - NCT06545747RecruitingPhase 3
MRI-guided radiation for advanced lung cancer
This trial tests a new way of giving radiation therapy for advanced lung cancer that cannot be surgically removed. It uses MRI scans to guide and adjust the radiation dose, which may help target the tumor more precisely and reduce side effects.
GuangzhouAges 18–75 - NCT06550427Recruiting
Lymphoma treatment response monitoring with genetic testing
This trial is testing a new way to monitor how well your lymphoma treatment is working. It uses a blood test to look for genetic changes in cancer cells, which may help doctors make better treatment decisions.
TaipeiAges 18 years+ - NCT06551649Recruiting
Test of cell-based treatment for ALS and MS
This study tests a therapy made from human amniotic cells to help reduce brain inflammation and damage. It may be an option for people with ALS or multiple sclerosis who meet the age and health requirements, as well as healthy volunteers to serve as a comparison group.
RomaAges 20–60 - NCT06552169RecruitingPhase 2
Treg cell therapy to lower anti-rejection meds after kidney transplant
This trial tests whether adding a special type of immune cell (Treg cells) to standard therapy can help kidney transplant recipients safely take lower doses of anti-rejection medicines. It is for people who are getting a kidney from a living donor.
Phoenix, ArizonaAges 18–65 - NCT06553872RecruitingPhase 2
Pirtobrutinib and CAR T-cell therapy for mantle cell lymphoma
This trial tests if adding the targeted therapy pirtobrutinib before CAR T-cell treatment (Tecartus) works better for mantle cell lymphoma that has come back or not responded to other treatments. It aims to improve outcomes for patients who are eligible for CAR T-cell therapy.
Stanford, CaliforniaAges 18 years+
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,684 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.